| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.015 | 0.6 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.6 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.6 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | -0.084 | 0.6 |
| mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |